

## Anti-BTLA [HMBT-6B2] Standard Size Ab01027-22.0

This chimeric hamster (Armenian) antibody was made using the variable domain sequences of the original Hamster IgG format, for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Hamster (Armenian) IgG, Kappa

Clone Number: HMBT-6B2

Alternative Name(s) of Target: CD272; B and T lymphocyte attenuator; B- and T-lymphocyte attenuator;

B and T lymphocyte associated protein; B- and T-lymphocyte-associated protein; BTLA1; FLJ16065;

MGC129743

**UniProt Accession Number of Target Protein: Q7TSA3** 

Published Application(s): Blocking, functional assays, immunoblot, IP, WB, FC

**Published Species Reactivity: Mouse** 

**Immunogen:** This antibody was raised by immunising Armenian hamsters with mouse BTLA:Fc fusion

protein.

**Specificity:** This antibody is specific for B and T lymphocyte attenuator (BTLA), which functions as a negative regulator of T cell activation and proliferation, and attenuates B cell proliferation upon associating with its known ligand, herpes virus entry mediator (HVEM).

**Application Notes:** This antibody has been used in immunoblot analyses to confirm that B and T lymphocyte attenuator (BTLA) regulates T cell activation through interaction with herpesvirus entry mediator (HVEM) (Sedy et al, 2005), as well as in FACS and yeast display technology to demonstrate that BTLA exhibits structural and expression polymorphisms and is highly induced in anergic CD4+ T Cells (Hurchla et al, 2005). In a mouse conjunctivitis model, treatment with this antibody during the induction phase has been shown to decrease B-cell population, upregulate Th2 cytokine production and increase the conjunctival eosinophile numbers (Ishida et al, 2012). However, treatment with this antibody during the effector phase does not affect the development of experimental conjunctivitis (Ishida et al, 2012).

**Antibody First Published in:** Waka Ishida et al. B and T lymphocyte attenuator regulates the development of antigen-induced experimental conjunctivitis. Graefes Arch Clin Exp Ophthalmol. 2012 Feb;250(2):289-95. PMID:21779950

**Note on publication:** Describe the use of this antibody, together with the anti-HVEM antibody, to investigate the roles that B and T lymphocyte attenuator (BTLA) and herpesvirus entry mediator (HVEM) play in the development of antigen-induced experimental conjunctivitis (EC).

## **Product Form**

**Size:** 200 μg Purified antibody.

**Purification:** Protein A affinity purified **Supplied In:** PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -

20°C.

Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic

© 2024 Absolute Antibody	https://absoluteantibody.com/product/anti-btla-hmbt-6b2/Ab01027
procedures for humans or animals.	